Gilder Gagnon Howe & Co. LLC Buys 16,394 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Gilder Gagnon Howe & Co. LLC lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,292 shares of the biopharmaceutical company's stock after buying an additional 16,394 shares during the period. Gilder Gagnon Howe & Co. LLC owned approximately 0.05% of TG Therapeutics worth $2,447,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in TG Therapeutics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after purchasing an additional 209,190 shares during the period. Clearbridge Investments LLC purchased a new position in TG Therapeutics during the fourth quarter worth $55,237,000. Charles Schwab Investment Management Inc. grew its position in shares of TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after purchasing an additional 84,904 shares during the period. Invesco Ltd. raised its stake in TG Therapeutics by 1.2% during the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company's stock worth $27,985,000 after purchasing an additional 10,989 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in shares of TG Therapeutics by 10.5% during the 4th quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company's stock worth $27,797,000 after purchasing an additional 87,679 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Down 1.6 %

Shares of NASDAQ:TGTX traded down $0.73 during midday trading on Friday, hitting $44.64. The company had a trading volume of 1,689,439 shares, compared to its average volume of 3,003,389. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a market cap of $7.09 billion, a price-to-earnings ratio of -446.31 and a beta of 2.14. The firm has a fifty day simple moving average of $38.28 and a 200 day simple moving average of $33.05.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. On average, analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.